What Does the Evidence Say About Tysabri and PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding the Shift from General Health to Exposure-Specific Risk

If you or a loved one is taking Tysabri, you may be worried about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that PML is a rare but serious complication linked to this medication. This page examines the limits of current evidence on long-term prognosis after PML, helping you understand what is known—and what remains uncertain.

Tysabri and PML: A Critical Safety Concern

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The long-term outcome of PML after Tysabri therapy is poor. The prescribing information states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This prognosis is consistent with the natural history of PML in other immunocompromised populations. Survivors often experience permanent neurological deficits, including cognitive impairment, motor dysfunction, and visual disturbances. The severity of disability depends on the extent of brain lesions and the timeliness of intervention.

Risk Factors and Monitoring for PML in Tysabri-Treated Patients

Three established risk factors increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment. The timeline between Tysabri exposure and documented PML harm varies. In clinical trials, PML occurred in three patients: two with multiple sclerosis treated for a median of 120 weeks (approximately 2.3 years) who had also received interferon beta-1a, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that the risk may persist after stopping therapy, and patients should continue to be monitored for new signs or symptoms suggestive of PML for at least six months following discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Regulatory Warnings and Prognosis Considerations

The adequacy of warnings regarding Tysabri and PML is addressed through a boxed warning, the most stringent warning required by the FDA. The boxed warning states that Tysabri increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also identifies the three risk factors and instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that the benefits of treatment outweigh the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For prognosis-related considerations, early detection and intervention are critical. Healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and dosing should be withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In multiple sclerosis patients, an MRI scan should be obtained prior to initiating therapy, as this may help differentiate subsequent multiple sclerosis symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For Crohn's disease patients, a baseline brain MRI may also be helpful to distinguish pre-existent lesions from newly developed lesions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, the long-term outcome of PML after Tysabri is generally poor, with high rates of death or severe disability. The risk is increased by anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. PML can occur during treatment or after discontinuation, necessitating continued monitoring. The boxed warning and restricted distribution program provide structured risk communication and mitigation, but the prognosis for affected patients remains grave.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for patients who develop PML after Tysabri therapy?

The long-term outcome of PML after Tysabri is generally poor. The prescribing information states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors often experience permanent neurological deficits, including cognitive impairment, motor dysfunction, and visual disturbances.

What are the main risk factors for developing PML while on Tysabri?

Can PML occur after stopping Tysabri?

Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should continue to be monitored for new signs or symptoms suggestive of PML for at least six months after stopping therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.